Compare BlackBerry Limited (BB) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs Bristol-Myers Squibb Co — how do they compare? BlackBerry Limited trades at $9.22 (market cap $5.27B), while Bristol-Myers Squibb Co trades at $63.52 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 24.7× BlackBerry Limited's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| BB | BMY | |
|---|---|---|
Market Cap | $5.27B | $129.94B |
Sector | Technology | Health |
52-Week High | $12.81 | $65.89 |
52-Week Low | $3.15 | $42.60 |
Enterprise Value | $5.14B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $8.83, down 1.67% on the day, with a neutral technical outlook despite recent earnings beats. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.06 versus $0.05 forecast, and revenue growth accelerating to 26% year-over-year in the latest quarter. Positive cash flow from operations of $16.5 million in 2025 marks a significant turnaround from previous years of negative operational cash flow.
While BlackBerry demonstrates strong momentum in QNX and secure communications segments with raised FY2027 guidance, the stock faces headwinds from premium valuation metrics (P/E 89.8, P/S 9.22) and execution risks in its automotive software transition. The 14.29% buy rating among analysts suggests cautious optimism, with the consensus price target of $10.50 implying 19% upside potential from current levels.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
